cipla vs ranbaxy research report

8/20/2019 Cipla vs Ranbaxy Research Report

1/39


2/39

.Assstant Pro"essorBhumika Bhayashaly

Research Metho(o!o)-/Sakshi !yai "ushyant Malik Pra#hi Ane$a


3/39

AC%N&'L("G(M(N!

I a% than0"#! to the a!%)ht- 1o( 'ho has )2en %e

the opport#nt- to e3press o#r sncere than0s an( (eep

post )ratt#(e to a!! those peop!e 'ho e3ten(e( ther

'ho!e hearte( co4operaton an( he!pe( %e co%p!etn)

the pro5ect report s#ccess"#!!-6

I 'o#!( !0e to than0 o#r %entor Miss. Shruti Mittal

'ho )#(e( %e a !ot co%p!etn) ths pro5ect report6

I a% a!so than0"#! to o#r (rector Mr. Sa#hin Goel7 'ho

)a2e %e s#ch opport#nt- to prepare a pro5ect report

that '!! enhance o#r practca! 0no'!e()e & corporate

a'areness6

Last +#t not the !east ! 'o#!( !0e to than0s to the

"raternt- o" SRCM "or %entorn)7 )#(n)7 s#pportn)7

teachn) & coachn) %e n "#!! capact- that has s#re!-

enrche( %- persona!t- as a 'ho!e6

Priyanshu Goel

Bhumika BhayashalySakshi !yai

"ushyant Malik Pra#hi Ane$a


4/39

DECLARATION

8e here+- (ec!are that ths pro5ect report s o#r o'n

research 'or0 an( to the +est o" %- 0no'!e()e &

+e!e"6 Matera! contans ths report nether pre2o#s!-

p#+!she( or 'rtten +- an- other person nor accepte(

"or the a'ar( o" an- other %aster (e)ree +- #n2erst-

o" h)her !earnn)6


5/39

PR()AC(

So%eone has r)ht!- sa( that practca!

0no'!e()e s "ar +etter than c!assroo% teachn)6

D#rn) ths pro5ect 'e "#!!- rea!9e( ths an( ca%e to

0no' a+o#t ho' a cons#%er chooses a%on) a 2are(

ran)e o" pro(#cts a2a!a+!e to h%6

Ths s the speca!9aton research pro5ect

on a co%part2e %ar0et st#(- o" Cp!a & Ran+a3-

Phar%ace#tca! +ran(s6 The o+5ect2e o" ths st#(- s to

)an 0no'!e()e a+o#t the %ar0et share an(

co%petton +et'een the t'o +ran(s6

D#rn) the pro5ect 'e researche( on ho'

the %ar0et share s capt#re( an( postonn) o" the

pro(#ct create( +- Cp!a an( Ran+a3- n the %n( o"

c#sto%ers6 A s#r2e- 'as a!so (one "or #n(erstan(n)

cons#%er +#-n) pattern an( pre"erences6

Th#s7 ths st#(- s +ase( on

co%part2e ana!-ss o" the %ar0et share +et''en the

+ran(s6


6/39

CONTENTS

Preface

Acknowledgement

Declaration

PART A

*. E3ec#t2e S#%%ar- :4;

+. In(#str- Pro$!e

,. Co%pan- Pro$!e ;?4


7/39

OVERVIE8 OF PHARMACEUTICAL

SECTOR

Acco#ntn) "or t'o percent o" the 'or!(s phar%ace#tca!%ar0et7 the In(an phar%ace#tca! sector has an est%ate(%ar0et 2a!#e o" a+o#t US +!!on6 Its at ;th ran0 n ter%s o"tota! phar%ace#tca! pro(#cton an( @=th n ter%s o" 2a!#e6 It s)ro'n) at an a2era)e rate o" B6: G an( s e3pecte( to )ro' toUS @: +!!on +- :?@?6

O2er the !ast t'o -ears the phar%ace#tca! %ar0et 2a!#e hasncrease( to a+o#t US =


8/39

the chan)es that too0 p!ace n the patent !a'7 chan)e o"

process patent to pro(#ct patent7 ha2e he!pe( n re(#cn) the

rs0 o" !oss "or nte!!ect#a! propert-6


9/39

CIPLA

Cp!a s one o" the !ar)est phar%a co%panes n the(o%estc %ar0et an( has presence n "or%#!atons an( +#!0

(r#)s %an#"act#rn)6 A!! the +#!0 (r#) %an#"act#rn)

"ac!tes o" the co%pan- ha2e +een appro2e( +- 2aro#s

a#thortes nc!#(n) the US FDA6 On the e3ports "ront7 the

co%pan- has strate)c a!!ances 'th )enerc %an#"act#res

s#ch as 8atson7 M-!an7 an( Te2e "or s#pp!- o" +#!0 (r#)s6

In#or4orate5 @>=<

Reistere5&6#e

Cp!a L%te(7 Cp!a Ho#se7 Penns#!a *#snessPar07 1anpatrao Ka(a% Mar)7 Lo'er Pare!7M#%+a ;?? ?@=

Chairman Dr6 Y#s#" K6 Ha%e(

Non7

(8e#uti9e:i#e7Chairman

Mr6 M6K6 Ha%e(

Listin E#t- Shares, *SE L%te( an( Natona! Stoc0E3chan)e o" In(a L%te(1!o+a! Depostor- Recepts, L#3e%+o#r) Stoc0E3chan)e

!urno9er USD @6B +!!on

(m4loyees :?7???J

A44ro9als US FDA7 8HO41ene2a7 MHRA4UK7 T1A4A#stra!a7SUKL4S!o2a0 Rep#+!c7 APVMA4A#stra!a7 MCC4So#th A"rca7 PIC41er%an-7 Dansh Me(ca!A)enc-7 ANVISA4*ra9!7 INVIMA4 Co!o%+a7 NDA4U)an(a7 Depart%ent o" Hea!th4Cana(a an( MOH4

Sa#( Ara+a7 a%on) others


10/39

;ihlihts Contn#o#s nno2aton n R &D 'th

=?J 'or!( $rsts6

O2er @7


11/39

It s an nte)rate(7 research +ase(7 nternatona!

phar%ace#tca! co%pan-7 pro(#cn) a '(e ran)e o"

#a!t-7 aor(a+!e )enerc %e(cnes7 tr#ste( +-hea!thcare pro"essona!s an( patents across )eo)raphes6

The Co%pan- has a )!o+a! "ootprnt n ;= co#ntres7 'or!(4

c!ass %an#"act#rn) "ac!tes n co#ntres an( ser2es

c#sto%ers n o2er @:< co#ntres6

In #ne :??7 Ran+a3- entere( nto an a!!ance 'th one o"

the !ar)est apanese nno2ator co%panes7 Dach San0-o

Co%pan- Lt(67 to create an nno2ator an( )enercphar%ace#tca! po'erho#se6

The co%+ne( entt- no' ran0s a%on) the top :?

phar%ace#tca! co%panes7 )!o+a!!-6


12/39

OBJECTIVES OF RESEARCH

The p#rpose o" research s to (sco2er ans'ers to #estons

thro#)h the app!caton o" scent$c proce(#res6 The %an a%

o" research s to $n( o#t the tr#th 'hch s h((en an( 'hch

has not +een (sco2ere( as -et6 Tho#)h each research st#(-

has ts o'n spec$c p#rpose +#t the research o+5ect2es can +e

!ste( nto a n#%+er o" +roa( cate)ores7 as "o!!o'n)

@6 To )an "a%!art- 'th a pheno%enon or to ache2e ne'

ns)hts nto t6 St#(es 'th ths o+5ect n 2e' are ter%e(

as e3p!orator- or "or%#!at2e research st#(es6

:6 To portra- acc#rate!- the characterstcs o" a partc#!ar

n(2(#a!7 st#aton or a )ro#p6 St#(es 'th ths o+5ect n

2e' are 0no'n as (escrpt2e research st#(es6=6 To (eter%ne the "re#enc- 'th 'hch so%ethn) occ#rs

or 'th 'hch t s assocate( 'th so%ethn) e!se6 St#(es

'th ths o+5ect n 2e' are 0no'n as (a)nostc research

st#(es6

;6 To test a h-pothess o" a cas#a! re!atonshp +et'een

2ara+!es6 S#ch st#(es are 0no'n as h-pothess4testn)research st#(es6


13/39

SIGNIFICANCE OF RESEARCH

A!! process s +orn o" n#r-6 Do#+t s o"ten +etter than

o2ercon$(ence7 "or t !ea(s to n#r- an( n#r- !ea(s to

n2enton6 Is a "a%o#s H#(son Ma3% n conte3t o" 'hch the

s)n$cance o" research can 'e!! +e #n(erstoo( Increase(

a%o#nts o" research %a0e pro)ress poss+!e6

Research nc#!cates scent$c an( n(#ct2e thn0n) an( t

pro%otes the (e2e!op%ent o" !o)ca! ha+ts o" thn0n) an(

or)an9aton6

The ro!e o" research n se2era! $e!(s o" app!e( econo%cs7

'hether re!ate( to +#sness or to the econo%- as a 'ho!e7 has

)reat!- ncrease( n %o(ern t%es6 The ncreasn) co%p!e3

nat#re o" +#sness an( )o2ern%ent has "oc#se( attenton on

the #se o" research n so!2n) operatona! pro+!e%s6 Research7

as an a( to econo%c po!c-7 has )ane( a((e( %portance7

+oth "or )o2ern%ent an( +#sness6


14/39

Researc Me!"#"$"%&

Research %etho(o!o)- s a 'a- to s-ste%atca!!- so!2e the

research pro+!e%6 It %a- +e #n(erstoo( as a scence o"

st#(-n) ho' research s (one scent$ca!!-6 In t 'e st#(- the

2aro#s steps that are )enera!!- a(opte( +- a researcher n

st#(-n) hs research pro+!e% a!on) 'th the !o)c +ehn(

the%6 It s necessar- "or the researcher to 0no' not on!- the

research %etho(s or techn#es +#t a!so the %etho(o!o)-6

Resear#h "esin<

!aret Po4ulation< Pop#!aton o" the research s thecons#%ers 'ho are 'e!! a'are o" the %e(cnes an( 'ho area+o2e @ -ears o" a)e6

Resear#h "esin < Descrpt2e Research

Sam4lin unit< Sa%e as the sa%p!e e!e%ent6

Sam4lin !e#hni=ue< Con2enence sa%p!n)6

Sam4le Si>e <


15/39

o#rna!s8e+stesReports

Data Ana!-ss

#es, Are You A?are &@ Ci4la Rana8y

Com4any 4ro5u#ts

Ans6 , .A/ YES .*/ N?

CIPLA

REN*AY

?

<

@?

@<

:?

:<

=?

=<

;?

;<


16/39


17/39

#es, "o You ;a9e Ci4la Rana8y Com4anyDs

Pro5u#t

Ans , .A/ YES .*/ NO

CIPLA PRODUCT RAN*AY PRODUCT

?

<

@?

@<

:?

:<

=?

=<

;?

;<

Cp!a G

Ran+a3- @;G

Peop!e #se Cp!a co%pan- pro(#ct %ore than Ran+a3-

pro(#ct6


18/39

#es, In 8hch Co%pan- Yo# Dea! 8th Most

Ans, .A/ Cp!a .*/ Ran+a3-

CIPLA RAN*AY

?

<

@?

@<

:?

:<

=?

=<

cp!a G

Ran+a3- =;G

Cp!a sa!es s %ore than Ran+a3-6


19/39

#es, 'hat Makes You !o Choose !his Com4any

Ans6 .A/ H)h De%an( .*/ H)h Pro$t

.C/ P#+!ct- O" Pro(#ct .D/ An- Other

A * C D

?

<

@?

@<

:?

:<

=?

=<

;?

;<

A BG * G C ;G D@:G


20/39

#es, 8hch Co%pan-s Pro(#ct Is H)h!- So!(

O#t


CIPLA RAN*AY?

<

@?

@<

:?

:<

=?

=<

Chart !itle

A8is !itle

A8is !itle

(A) CIPLA 66%

(B) RANBAXY 34%


21/39

#es, 'hi#h Com4any Gi9es You ;iher

ProEt


;G

=G

ProEt Marin

CIPLA

RAN*ACY

(A) CIPLA 64%

(B) RANBA! "6%


22/39

#es, Commonly You Sale Any Me5i#ine

&n !he Pres#ri4tion &@

Ans, .A/ Doctor

.*/ Che%st

.C/ M6R

.D/An- Other

DOCTORCHEMIST

M6RANY OTHER

?G


23/39


24/39

#es, Amon Ci4la Rana8y 'hi#h

Com4any You )oun5 Reliale

Ans, .A/ Cp!a .*/

Ran+a3-

:G

=G

Re!a+!t-

CIPLA

RAN*AY

.A/ CIPLA :G

.*/ RAN*AY =G


25/39

#es, 12e Yo#r Sats"acton Le2e!

Ans, .A/ E3ce!!ent .*/ 1oo((C) Satisfactory (D) A!ra"!

ECELLENT 1OOD SATISFACTORY AVERA1E

?

:

;

@?

@:

@;

@

@

:?

(A) EXCELLENT 36%

(B) #OOD 34%

(C) SATIS$ACTORY &%

(D) A'ERA#E &%


26/39

#es, 'hi#h Com4any Pro9i5es Most

:arious Promotional S#hemes !o You

Ans6 .A/ Cp!a

.*/Ran+a3-

CIPLA RAN*AY?G


27/39

UE6@@ 8HICH TYPES OF SCHEMES ARE

OROVIDED *Y THE COMPANY TP YOU

ANS6 .A/ ETRA COMMISSION

.*/ 1OOD PROFIT MAR1IN

.C/ ANY SHORT OF CONTEST

?<

@?@<:?:<=?

:>

@=

(A) EXTRA COISSION 6%

(B) #OOD PRO$IT AR#IN *+%

(C) ANY S,ORT O$ CONTEST 6%


28/39

UE6@: 8ETHER CONSUMER S8ITCH OVER

TO OTHER COMPANY

OR NOT IF THEIR *RAND IS NOT AVAILA*LE

ANS6 .A/ YES .NO/

YES NO?

<

@?

@<

:?

:<

=?

Chart !itle

A8is !itle

(A) YES 44%

(B) NO *6%


29/39

UE6@= 8HICH PRODUCT YOU 8ILL SU11EST TO

THE CONSUMER

ANS6 .A/ CIPLA .*/

RAN*AY

G

=;G

Chart !itle

CIPLA

RAN*AY

(A) CIPLA 66%

(B) RANBAXY 34%


30/39

UE6@; IN 8HICH SEASONAL VARIATION THE

DEMAND OF MEDICINE VARRIES

ANS6 .A SUMMER

.*/ 8INTER

.C/ ANY OTHER

SUMMER 8INTER ANY OTHER?

<

@?

@<

:?

:<

=?

=<

;?

Chart !itle

A8is !itle

(A) S-ER .%

(B) /INTER &%

(C) ANY OT,ER +%


31/39

UE6@< 8HAT IS THE PRICE DIFFERENTIATION

*ET8EEN THE MEDICINE

ANS6 .A/ LESS .*/

CONSTANT

.C/ MORE .D/ VARIED

LESS

CONSTANT

MORE

VARIED

? < @? @< :? :< =?

@@

:;

B

Chart !itle

.A/ LESS ::G

.*/ CONSTANT ;G

.C/ MORE @;G

.D/ VARIED @G


32/39


33/39

FINDIN1S

• /! 0a! co12ar! ot0 2ro5cts o 1ay as!s 7i8! ra a75!9

2ro5ct 2ositioi"9 c5sto1!r 2r!f!r!c!9 :5a7ity9 2ric!9 !tc a

fo5 t0at Ci27a i a77 r!s2!cts !tt!r t0a Raa;y<

• D5ri" t0! s5r!y =! fo5 t0at 5>affara"ar 0as a 05"! 1ar8!t

of t0! 20ar1ac!5tica7 i5stry<

• ost of t0! 2!o27! 25rc0as!s 1!ici!s o7y =it0 cos57ti" Doctor

(!! for co11o is!as! ? sic8!ss) a 5s! 1!ici!s ras

2r!scri! y Doctors or 1!ica7 stor!s or R<• '!ry f!= 2!o27! 8o= ao5t 1!ici!s ras i

coscio5s


34/39

LIMITATIONS

In e2er- st#(-pro5ect #n(erta0en !%tatons arses an( are

ne2ta+!e6

S%!ar!- n ths pro5ect se2era! !%tatons appear7 'hch 'o#!(

ha2e +een e!%nate( +- the #se o" t%e7 access+!t- to

n"or%aton has not +een poss+!e6

• T#i$ ro&ect i$ 'a$ed on 051a 2roc!ssi" ? aa7ysis T#erefore t#ere

are c#ance$ of #*man error

• +ne of t#e ma&or limitation$ i$ ti1! o5!!ss

• Trainee$ are not 'eing 2art of or"ai>atio T#e, are merel, con$idered

a$ trainee$

• Trainee$ are ro-ided wit# limited re$o*rce$ No finanal aid or $tiend i$

'eing aid to t#em $o t#e, can not $end m*c# on meeting$ wit# t#e

otential c*$tomer$ It can 'e al$o treated a$ a limitation of cost

o5!!ss

• La$t '*t not t#e lea$t i$ t#e limitation of ar!a o5!!ss


35/39

SU11ESTIONS & RECOMMENDATIONS

• T0! co12ai!s s0o57 icr!as! a=ar!!ss of t0!ir 2ro5cts a

ras y 2ro2!r a!rtis!1!ts<

• A=ar!!ss of co11o 1!ici!s s0o57 ! icr!as!9 so t0at t0!y

ca ! 25rc0as! =it0o5t cos57tatio of octors i cas! of

!1!r"!cy<

• Pric!s of 1!ici!s s0o57 ! r!5c! as =! o= 0a! "!!ric ty2! of

1!ici!s =0ic0 2roi!s a 0i"0 2rofit 1ar"i to 1!iators9

r!s57ti" i icr!as! of 1ar8!t 2ric! of 1!ici!s t0at ca@t !

affora7! y co11o 2!o27!<

• E;2iry at! of 1!ici!s s0o57 ! Bo7 a c7!ar7y isi7!<

• Istr5ctios for 5s! s0o57 ! ic75! o 1!ici!s<

• O7i! s0o22i" of 1!ici!s (i

itro5c!<

• Raa;y s0o57 foc5s o its 1ar8!ti" ? 2ositioi" strat!"y to

o!rco1! t0! "a2 ? sa7!s i co12ariso to Ci27a


36/39

Conc!#sons


37/39

*+!o)raph-


38/39

Anne3#re


39/39

cipla vs ranbaxy research report

Documents